| Literature DB >> 29789714 |
Jie Ding1,2, Chiuan-Ren Yeh2, Yin Sun2, Changyi Lin2, Joshua Chou2, Zhenyu Ou2, Chawnshang Chang2, Jun Qi3, Shuyuan Yeh4.
Abstract
Recent studies indicated that the estrogen receptor beta (ERβ) could affect the progression of prostate and bladder tumors, however, its roles in the renal cell carcinoma (RCC), remain to be elucidated. Here, we provide clinical evidence that ERβ expression is correlated in a negative manner with the overall survival/disease-free survival in RCC patients. Mechanism dissection revealed that targeting ERβ with ERβ-shRNA and stimulating the transactivation of ERβ with 17β-estradiol or environmental endocrine disrupting chemicals, all resulted in altering the lncRNA HOTAIR expression. The ERβ-modulated HOTAIR is able to function via antagonizing several microRNAs, including miR-138, miR-200c, miR-204, or miR-217 to impact various oncogenes, including ADAM9, CCND2, EZH2, VEGFA, VIM, ZEB1, and ZEB2, to promote RCC proliferation and invasion. Together, the identification of the ERβ-HOTAIR axis may provide us new biomarkers and/or therapeutic targets to better suppress RCC progression in the future.Entities:
Mesh：
Substances：
Year: 2018 PMID： 29789714 DOI： 10.1038/s41388-018-0175-6
Source DB: PubMed Journal: Oncogene ISSN： 0950-9232 Impact factor: 9.867